Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab

Area of Science:

• Neuroimaging
• Neurology
• Biomarkers

Background:

• Magnetization transfer ratio (MTR) is a sensitive MRI metric reflecting tissue microstructural integrity, including myelination and axonal density.
• Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system characterized by progressive tissue damage.

Purpose of the Study:

• To investigate the effect of alemtuzumab on MTR in normal-appearing grey matter (NAGM) and white matter (NAWM) in patients with multiple sclerosis.
• To assess whether alemtuzumab treatment can halt or slow down tissue degeneration in MS.

Main Methods:

• Longitudinal MRI study comparing MTR changes in untreated MS patients and alemtuzumab-treated MS patients.
• Analysis of mean MTR in NAGM and NAWM over time, with age-adjustment for grey matter analysis.

Main Results:

• Untreated MS patients showed significant decreases in MTR in both NAGM (-0.25 pu/year) and NAWM (-0.12 pu/year).
• Alemtuzumab-treated MS patients exhibited stable MTR in both NAGM (-0.01 pu/year) and NAWM (-0.02 pu/year), with no significant decline.
• Age-adjusted gradient difference in grey matter was significant (0.25 pu/year) in untreated patients, but not in treated patients.

Conclusions:

• Alemtuzumab treatment appears to protect against tissue damage in normal-appearing grey and white matter in multiple sclerosis patients.
• The protective effect may be attributed to alemtuzumab's ability to prevent new lesion formation and preserve tissue integrity.